Real-World check: cystic fibrosis drug holds up after approval
NCT ID NCT02194881
First seen Nov 20, 2025 · Last updated May 17, 2026 · Updated 19 times
Summary
This study looked at 57 French cystic fibrosis patients aged 6 and older with a G551D mutation who were taking Ivacaftor. Researchers wanted to see if the drug remained effective and safe in everyday use after it was approved. They measured lung function, hospital stays, and antibiotic use over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.